A narrative review published in Epigenomics on 10 August 2026 sets out to map a class of molecules that conventional genome annotation spent decades ignoring: the microproteins encoded by short open reading frames. Among the handful the authors single out as well studied, MOTS-c appears alongside Humanin, Myoregulin, DWORF, HOXB-AS3-p, Mitoregulin and CASIMO1.

That framing is the reason the paper is worth reading. In peptide circles the MOTS-c peptide is usually discussed on its own, as a compound with a list of reported effects. The review puts it back where it came from, inside a molecular class with shared origins and shared regulatory machinery.

What sORF-encoded microproteins are

The authors write that the human genome contains hundreds of thousands of short open reading frames, and that their translational products, which they call sORF-encoded microproteins and note were historically termed micropeptides, have long remained overlooked in conventional genome annotation.

The reason is mundane. Annotation pipelines applied a minimum length cutoff, on the assumption that reading frames below a certain size were noise rather than genuine coding sequence. The review reports that increasing evidence now demonstrates these molecules play critical regulatory roles in human physiology and disease.

The examples the authors give span three areas: cardiometabolic disease, neurodegeneration and cancer. MOTS-c and Humanin, both encoded in mitochondrial DNA, sit on the cardiometabolic side of that list.

Where the MOTS-c peptide came from

The MOTS-c peptide entered the literature in 2015, in a Cell Metabolism paper describing it as a mitochondrial-derived peptide and reporting effects on metabolic homeostasis, obesity and insulin resistance in the models used. FDA’s own briefing document describes it as a peptide consisting of 16 amino acids.

Two later papers are worth naming for anyone tracing the mechanism. A 2018 Cell Metabolism study reported that MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress, which is an unusual behaviour for a peptide of that size and part of why the molecule attracted attention. A 2023 review in the Journal of Translational Medicine collected the reported effects and proposed mechanisms across stress, metabolism and ageing.

None of that literature involves approved clinical use. The compound remains a research subject.

What the new review adds

The contribution of the Epigenomics paper is not new experimental data. It is a description of how expression of these microproteins is controlled.

The authors report that expression is tightly regulated by epigenetic mechanisms, and they name three: DNA methylation, Polycomb-mediated H3K27 trimethylation, and bivalent histone modifications. They add a fourth layer, epitranscriptomic regulation through N6-methyladenosine-mediated translation, usually written m6A.

That matters for how the class is studied. If a microprotein’s abundance is set by reversible chemical marks on DNA, on the histones that package it, and on the RNA transcript, then the molecule is not simply present or absent in a tissue. It is dialled up and down by an upstream system, and experiments that measure the peptide without accounting for that system may be measuring the wrong variable.

The authors also survey emerging strategies in the field, listing epigenome editing, peptide replacement, and immunopeptidome-based neoantigen targeting. They describe these as emerging, not established. Their closing characterisation is that the sORF-encoded microproteome represents an epigenetically integrated and functionally significant regulatory layer of the human proteome.

What a narrative review is, and is not

This is a narrative review, and the distinction from a systematic review is not pedantry.

A systematic review pre-specifies its search, screens against stated criteria, and reports what it excluded. A narrative review selects and synthesises according to the authors’ judgement. It is well suited to mapping a young field and poorly suited to answering whether a specific effect is real, because nothing constrains which studies make it in.

So the review is a good map of what the microprotein field currently believes about itself. It is not evidence that any individual finding about the MOTS-c peptide has been replicated, and it reports no new results for the compound. Readers who want the underlying evidence will need the primary papers, starting with the two Cell Metabolism studies.

The regulatory picture is separate

MOTS-c was one of seven peptides in front of FDA’s Pharmacy Compounding Advisory Committee on 23 July 2026, alongside BPC-157, KPV, TB-500, Emideltide, Epitalon and Semax. The uses FDA evaluated for MOTS-c were obesity and osteoporosis, and the agency’s briefing document proposed that neither MOTS-c free base nor MOTS-c acetate be added to the 503A Bulks List. We covered the committee’s votes and what they do and do not change when the meeting concluded.

The two documents sit oddly next to each other, and the contrast is instructive. A peer-reviewed review describes MOTS-c as a functionally significant regulatory molecule. A regulatory evaluation of the same compound concludes it is not well characterised. Both can be accurate, because they are asking different questions. The review asks what the molecule does in biology. The agency asks whether the substance, as it would actually be supplied and compounded, is defined well enough to be used in a human drug product.

What this means for laboratory work

FDA’s briefing document is unusually specific about what it could not find, and that list doubles as a checklist.

For MOTS-c free base, the agency writes that quality control attributes including impurities, aggregates and endotoxins were not found in the publicly available scientific literature, and that the nomination package lacked a certificate of analysis. It also notes an absence of water solubility data, which it says makes it difficult to draw a conclusion about product performance in the proposed injectable form. Both forms are described as carrying inconsistent naming conventions that do not follow INN, IUPAC or USAN standards.

On storage, the document reports that lyophilised MOTS-c free base is expected to be stable when kept below minus 20 degrees Celsius, desiccated and protected from light, and that the acetate form is expected to be stable below minus 20 degrees Celsius under the reported conditions.

Those are the fields worth reading first in any supplier documentation before the compound enters an assay, because impurities and aggregates are exactly what confound a low-abundance peptide measurement. Our MOTS-c research reference material and the European research buyer guide cover the procurement side, including what a complete document set should contain.

References

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.

author-avatar

About Peptra Labs Research

The Peptra Labs research desk follows peptide science: new peer-reviewed studies, EU and US regulatory decisions, and clinical trial results. Every article cites its primary sources. All compounds discussed are for laboratory research use only.

Newer
GLP-1 Receptor Agonists: One Method Now Identifies 9
Back to list
Older KPV Peptide Research Moves Into Metabolism: First Adipocyte Study Reported

Related Posts